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Abstract: 
Colorectal cancer (CRC), commonly known as bowel cancer is the third most 
common cause of cancer-related deaths in the western world.  Colorectal 
cancer is one of the leading malignancies worldwide. CRC has been reported to 
show geographical variation in its incidence, even within areas of ethnic 
homogeneity. The usual treatment is surgery and subsequent chemotherapy and 
radiotherapy. Cancer development and progression is dictated by series of 
alterations in genes such as tumor suppressor genes, DNA repair genes, 
oncogenes and others. In colorectal carcinogenesis disturbances different from 
mutations called an epigenetic regulation are also taken into consideration.  
The aim of this study was to study the promoter hypermethylation of CpG 
islands of p16 gene in colorectal cancer patients among the Kashmiri 
population. The study included 70 surgically obtained colorectal samples 
among which 50 were obtained from colorectal cancer patients and 20 were 
histopathologically normal colorectal samples. All the samples were 
histopathologically confirmed before further processing. DNA was extracted 
from all the samples and was modified using bisulphite modification kit. 
Methylation-specific polymerase (MSP) chain reaction was used for analysis of 
the promoter hypermethylation status of p16 gene. The genetic analysis of the 
cases and controls by MSP- PCR method, for checking the promoter 
hypermethylation of CpG islands of p16 gene revealed that unlike other high 
risk regions, Kashmiri population has a different promoter hypermethylation 
profile of p16 gene. 66% of the cases showed p16 promoter hypermethylation 
while as 34% of the cases were nonhypermethylated. The study also revealed 
that 20% of the normal cases also had promoter hypermethylation of p16 gene 
and 80% did not showed promoter hypermethylation of p16 gene. The 
association of promoter hypermethylation with colorectal cancer was evaluated 
by χ2 (Chi square) test with Odds ratio and was found to be significant. Among 
29 male cases and 21 female cases, the association of promoter 
hypermethylation with colorectal cancer was evaluated using Fisher’s exact 
test and was found to be significant in both males and females. Occurrence of 
p16 promoter hypermethylation was found to be unequally distributed in males 
and females with more frequency in males than in females but the difference 
was not statistically significant. When the frequency of p16 promoter 
hypermethylation was compared with clinical staging of the disease, p16 
promoter hypermethylation was found to be certainly higher in Stage III/IV 
(83.33%) compared to Stage I/ II (56.25%) but the difference was not 
statistically significant. Also, the degree of p16 promoter hypermethylation 
increased with the increasing severity of the lesion but the difference was not 
again statistically significant. 
These results clearly suggest that p16 aberrant promoter hypermethylation in 
Kashmiri population contributes to the process of carcinogenesis in colorectal 
cancer and is reportedly one of the commonest epigenetic changes in the 
development of human CRC. It also demonstrates that hypermethylation of p16 
gene can be designated as epigenetic biomarker for the screening, diagnosis 
and prognosis of colorectal cancer. The data gives a clue that p16 gene 
expression can be readily and fully restored and growth rate of cancer cells 
decreased by treatment of cancer cells with demethylating agents and DNA 
methylation inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
1.1. COLORECTAL CANCER: 
Colorectal cancer, also called colon cancer or large bowel cancer includes 
cancerous growths in the colon, rectum and appendix. With 6,55,000 deaths 
worldwide per year, it is the fifth most common form of cancer in the United 
States and the third leading cause of cancer-related deaths in the Western 
world (World Health Organization, 2006 and National Cancer Institute, 2009). 
Colorectal cancer being the commonest cancer is the major cause of mortality 
and morbidity worldwide, there are nearly one million new cases of colorectal 
cancer diagnosed world-wide each year and half a million deaths (Boyle and 
Elena, 2002). It is a commonly diagnosed cancer in both men and women. In 
2008, about 1, 48, 810 new cases were diagnosed in U.S and almost 49,960 
deaths from colorectal cancer were speculated (Cancer Facts and Figures, 
2008). The incidence of this malignancy shows considerable variation among 
racially or ethnically defined populations in multiracial/ethnic countries. 
Kashmir has been reported by now as a high-incidence area of GIT cancers 
(Shah et al., 1990; Mir et al., 2005; Salam et al., 2009). Colorectal Cancer in 
Kashmir valley is the third most common GIT cancer after esophageal and 
gastric cancer (Sameer et al., 2009). The development of CRC is a multistep 
process, which can arise due to the cumulative effect of mutations in various 
different proto-oncogenes, tumor suppressor genes, and/or from epigenetic 
changes in DNA (Vogelstein et al., 1988; Fearon et al., 1990; Mustafa et al., 
2007). Colorectal cancer is a disease originating from the epithelial cells lining 
the colon or rectum of the gastrointestinal tract, as a result of mutations to 
some of the genes. Some of the mutations are inherited, and others are 
acquired (Ionov et al., 1993; Chakravarthi et al., 1999). Some genes are 
oncogenes - they are over expressed in colorectal cancer. RAS, RAF, and PI3K, 
which normally encourage the cell to divide in response to growth factors, can 
become mutated with mutations that make them over signal the cell. There are 
two major mechanisms of gene inactivation. One is the genetic mechanism, i.e. 
the aberration of DNA structure such as homozygous deletion or intragenic 
mutation resulting in the gene inactivation. The other is the epigenetic 
mechanism, i.e., the methylation of the position 5 of cytosine (C) leading to the 
lack of gene expression, while the structure and the product of the gene remain 
unchanged. 
DNA methylation is a naturally occurring event in both prokaryotic and 
eukaryotic organisms. In prokaryotes DNA methylation provides a way to 
protect host DNA from digestion by restriction endonucleases that are 
designed to eliminate foreign DNA, and in higher eukaryotes DNA 
methylation functions in the regulation/control of gene expression (Costello et 
al., 2001). It has been demonstrated that aberrant DNA methylation is a 
widespread phenomenon in cancer and may be among the earliest changes to 
occur during oncogenesis (Stirzaker, 1997). DNA methylation has also been 
shown to play a central role in gene imprinting, embryonic development, 
chromosome gene silencing, and cell cycle regulation. In many plants and 
animals, DNA methylation consists of the addition of a methyl group to the 
fifth carbon position of the cytosine pyrimidine ring via a methyltransferase 
enzyme (Adams, 1995). The majority of DNA methylation in mammals occurs 
in 5’-CpG-3’ dinucleotides, but other methylation patterns do exist. In fact, 
about 80 percent of all 5’-CpG-3’ dinucleotides in mammalian genomes are 
found to be methylated, whereas the majority of the 20 percent that remain 
unmethylated are within promoters or in the first exons of genes.     
In higher order eukaryotes, DNA is methylated only at cytosines located 5’ to 
guanosine in the CpG dinucleotide and this modification has important 
regulatory effects on gene expression, especially when involving CpG rich 
areas known as CpG  islands, located in the promoter region of many genes. 
While almost all gene-associated islands are protected from methylation on 
autosomal chromosomes, extensive methylation of CpG islands has been 
associated with transcriptional inactivation of selected imprinted genes and the 
genes on inactivated X chromosome of females. Aberrant methylation of 
normally unmethylated CpG islands has been associated with transcriptional 
inactivation of gene (Zingg et al., 1997). It is a complex process catalyzed by 
DNA methyltransferases (Dnmts). The methyl group is donated by the 
universal methyl donor s-adenosyl L -methionine. Unmethylated CpGs are 
grouped in clusters called CpG islands that are present in the 5' regulatory 
regions of many genes. In many disease processes such as cancer, gene 
promoter CpG islands acquire abnormal hypermethylation, which results in 
transcriptional silencing (Jaenisch et al., 2003). DNA methylation may affect 
the transcription of genes in two ways. First, the methylation of DNA may 
itself physically impede the binding of transcriptional proteins to the gene and 
secondly, and likely more important, methylated DNA may be bound by 
proteins known as methyl-CpG-binding domain proteins (MBDs). MBD 
proteins then recruit additional proteins to the locus, such as histone 
deacetylases and other chromatin remodeling proteins that can modify 
histones, thereby forming compact, inactive chromatin termed silent 
chromatin. Promoter hypermethylation is one of the hallmarks of 
carcinogenesis associated with transcriptional silencing and loss of expression 
of genes encoding for diverse cellular pathways (Esteller, 2007). Most of the 
evidence exists for tumor suppressor genes (Issa, 2004; Laird, 2005).  
Hypermethylation leads to silencing of gene transcription through a complex 
process involving chromatin condensation and histone deacetylation (Jones et 
al., 1998; Wade et al., 1999). 
The ability to detect and quantify DNA methylation efficiently and accurately 
has become essential for the study of cancer, gene expression, genetic disease, 
as well as many other important aspects of biology. To date a number of 
methods have been developed to detect/quantify DNA methylation including: 
high- performance capillary electrophoresis (Fraga et al., 2000) and 
methylation-sensitive arbitrarily primed PCR (Gonzalgo, 1997). However, the 
most common technique used today remains the bisulfite conversion method 
(Frommer, 1992).This technique involves treating methylated DNA with 
bisulfite which converts unmethylated cytosines into uracil. Methylated 
cytosines remain unchanged during the treatment. Once converted the 
methylation profile of the DNA can be determined by PCR amplification 
followed by DNA sequencing.  
1.2. P16 GENE 
Epigenetic silencing through DNA methylation can begin very early in tumor 
progression and may affect multiple genes involved in different cellular 
pathways including cell cycle control, DNA repair and many others (Baylin et 
al., 1998; 2001). Promoter hypermethylation can cause transcriptional 
inactivation of tumor suppressor gene like p16. Human p16 gene possesses a 
CpG island in the promoter region and it has been reported that the 
methylation of discrete regions of the p16 CpG island is associated with the 
silencing of the gene. Promoter hypermethylation of p16 gene in colorectal 
cancer patients has been studied and documented in several studies. Some 
studies have suggested that p16 plays an important role in cancer pathogenesis 
and has implications for improving the clinical management (Lam et al., 
2008). Methylation of the p16 (INK4a) gene contributes to the process of 
carcinogenesis in colorectal cancer and is useful as a prognostic factor in the 
early stage (Yi Jing et al., 2001; Ishiguro et al., 2006). P16 might act as a 
tumor suppressor in colorectal carcinomas and was more frequently 
methylated in advanced colorectal carcinomas (Hibi et al., 2005; Goto et al., 
2008). P16 hypermethylation plays a role in the carcinogenesis of colorectal 
cancers (Liang et al., 1999). The p16 (CDKN2a/INK4a) gene is an important 
tumor-suppressor gene and it is located on human chromosome 9 in the region 
9p21, involved in the p16/cyclin dependent kinase/retinoblastoma gene 
pathway of cell cycle control, in which the p16 protein is considered to be a 
negative regulator involved in the inhibition of G1 phase progression (Rocco et 
al., 2001). Since its discovery as a CDKI (cyclin-dependent kinase inhibitor) in 
1993, the tumor suppressor p16 has gained widespread importance in cancer. It 
is also called as INK4A or MTS-1 or CDKN2A. Different alternatively spliced 
gene products are encoded by p16: Protein P16 and p14ARF Protein. The 
human p16 protein is a 16-KD protein containing 156 amino acids and was 
first discovered in a yeast two-hybrid system to detect proteins that interact 
with human cyclin Dependent kinase (Ruas et al., 1998). Its mechanism of 
action as a CDKI has been elegantly elucidated and involves binding to and 
inactivating the cyclin D-cyclin-dependent kinase 4 (or 6) complex, and thus 
renders the retinoblastoma protein unphosphorylated and inactive. This effect 
blocks the transcription of important cell-cycle regulatory proteins that 
promote passage of the cell through the restriction point of the G1 stage and 
results in cell-cycle arrest (Liggett et al., 1998). Cyclin-dependent kinase 
inhibitor 2A (p16 inhibits CDK4), also known as CDKN2A, is a tumor 
suppressor protein, which in humans is encoded by the CDKN2A gene having 
three exons (Entrez Gene; Nobori et al., 1994; Stone et al., 1995). P16 plays 
an important role in regulating the cell cycle, and mutations in p16 increase the 
risk of developing a variety of cancers, notably melanoma. P16 inactivation 
breaks down the regulatory mechanism of the cell cycle. As a tumor 
suppressor gene, being silenced by any mechanism will promote 
carcinogenesis. This gene generates several transcript variants which differ in 
their first exons. At least three alternatively-spliced variants encoding distinct 
proteins have been reported, two of which encode structurally related isoforms 
known to function as inhibitors of CDK4 kinase. The remaining transcript 
includes an alternate first exon located 20 Kb upstream of the remainder of the 
gene; this transcript contains an alternate open reading frame (ARF) that 
specifies a protein which is structurally unrelated to the products of the other 
variants. This ARF product functions as a stabilizer of the tumor suppressor 
protein p53 as it can interact with, and sequester, MDM2, a protein responsible 
for the degradation of p53 (Molecular biology of cancer, Oxford University 
Press, 2005). In spite of the structural and functional differences, the CDK 
inhibitor isoforms and the ARF product encoded by this gene, through the 
regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a 
common functionality in cell cycle G1 control. This gene is frequently mutated 
or deleted in a wide variety of tumors, and is known to be an important tumor 
suppressor gene. Increased expression of the p16 gene as organisms age 
reduces the proliferation of stem cells (Krishnamurthy et al., 2006). This 
reduction in the division and production of stem cells protects against cancer 
while increasing the risks associated with senescence. Mutations in the 
CDKN2A gene are associated with increased risk of a wide range of cancers 
and alterations of the gene are frequently seen in cancer cell lines. Pancreatic 
adenocarcinoma is often associated with mutations in the CDKN2A gene 
(Caldas et al., 1994; Bartsch et al., 1995; Liu et al., 1995). Homozygous 
deletion of p16 is frequently found in esophageal cancer and gastric cancer cell 
lines (Igaki et al., 1994). Concentrations of p16INK4a increase dramatically as 
tissue ages. Therefore p16INK4a could potentially be used as a blood test that 
measures how fast the body's tissues are aging at a molecular level (Liu et al., 
2009). The inactivation of p16INK4a gene due to aberrant promoter 
hypermethylation in esophageal, lung, gastric and hepatocellular carcinoma 
has been well documented (Hibi et al., 2001; Huang et al., 2004; Qing et al., 
2005; Liu et al., 2006; Belinsky et al., 2006; Abbaszadegan et al., 2008; Salam 
et al., 2009). However, before accepting the conclusion that hypermethylation 
of tumor suppressor gene promoter is invariably the cause of gene inactivation, 
it is worth evaluating the data a bit more critically. Epigenetic mechanisms of 
gene inactivation, including promoter hypermethylation, are undoubtedly 
important in cancer development and represent an alternative means of 
inactivating tumor suppressor genes. Nevertheless, the standard of proof for 
establishing that hypermethylation of the promoter of any given gene has a 
critical role in loss of gene expression and cancer development should 
probably be set quite high, regardless of whether the gene is a well-established 
tumor suppressor gene, like p16, or a potential tumor suppressor gene. 
There are contradictory reports regarding p16 promoter hypermethylation in 
the etiology of various cancers including colorectal cancer. The present study 
is an attempt to analyze the p16 gene promoter hypermethylation in colorectal 
carcinoma in Kashmiri population. As this aspect has not been well studied in 
colorectal carcinoma patients of Kashmir valley. So the study was confined to 
study the promoter hypermethylation of p16 gene in colorectal patients of 
Kashmir, which may help in prognosis and diagnosis of the disease so that 
further preventive measures could be taken.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature: 
2.1 Cancer 
Cancer, medically called a malignant neoplasm, is a term for a large group of 
different diseases. In cancer, cells divide and grow uncontrollably, 
forming malignant tumors, and invade nearby parts of the body. The cancer 
may also spread to more distant parts of the body through the lymphatic 
system or bloodstream. Not all tumors are cancerous. Benign tumors do not 
grow uncontrollably, do not invade neighbouring tissues, and do not spread 
through the body. Healthy cells control their own growth and will destroy 
themselves if they become unhealthy. Cell division is a complex process that is 
normally tightly regulated. Cancer happens when problems in the genes in a 
cell prevent these controls from working. These problems with genes may be 
from damage to the gene or may be inherited. Damage to genes can come from 
many sources inside or outside of the cell. Faults in two types of genes are 
especially important: oncogenes, which drive the growth of cancer cells, 
and tumor suppressor genes, which prevent cancer from developing. 
2.1.1 Causes 
Determining what causes cancer is complex and it is often impossible to assign 
a specific cause for a specific cancer. Many things are known to increase the 
risk of cancer including tobacco use, infection, radiation, lack of physical 
activity, poor diet and obesity, and environmental pollutants (Anand et 
al., 2008). These can directly damage genes or combine with existing genetic 
faults within cells to cause the disease (Kinzler et al., 2002). A small 
percentage of cancers, approximately five to ten percent, are entirely 
hereditary. 
Cancer can be detected in a number of ways, including the presence of 
certain signs and symptoms, screening tests, or medical imaging. Once a 
possible cancer is detected it is diagnosed by microscopic examination of 
a tissue sample. Cancer is usually treated with chemotherapy, radiation 
therapy and surgery. The chances of surviving the disease vary greatly by the 
type and location of the cancer and the extent of disease at the start of 
treatment. While cancer can affect people of all ages, and a few types of cancer 
are more common in children. The risk of developing cancer generally 
increases with age. In 2007, cancer caused about 13% of all human 
deaths worldwide (7.9 million). Rates are rising as more people live to an old 
age and as mass lifestyle changes occur in the developing world (Jemal et al., 
2011). 
Cancers are primarily an environmental disease with 90-95% of cases 
attributed to environmental factors and 5-10% due to genetics (Anand et 
al., 2008). Environmental, as used by cancer researchers, means any cause that 
is not genetic, not merely pollution. Common environmental factors that 
contribute to cancer death include tobacco (25-30%), diet and obesity (30-
35%),  infections  (15-20%),  radiation (both ionizing and non-ionizing, up to 
10%), stress, lack of physical activity, and environmental pollutants (Anand  et 
al.,  2008). Cancer pathogenesis is traceable back to DNA mutations that 
impact cell growth and metastasis. Substances that cause DNA mutations are 
known as mutagens, and mutagens that cause cancers are known as 
carcinogens. Many mutagens are also carcinogens, but some carcinogens are 
not mutagens. Alcohol is an example of a chemical carcinogen that is not a 
mutagen (Seitz  et al., 1998). In Western Europe 10% of cancers in males and 
3% of cancers in females are attributed to alcohol (Schutze, 2011). 
Decades of research has demonstrated the link between tobacco use and cancer 
in the lung, larynx, head, neck, stomach, bladder, kidney, esophagus and 
pancreas (Kuper et al., 2002). Tobacco smoke contains over fifty known 
carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons 
(Kuper et al., 2002). Tobacco is responsible for about one in three of all cancer 
deaths in the developed world (Sasco et al., 2004) and about one in five 
worldwide ( Kuper  et al., 2002). Diet, physical inactivity, and obesity are 
related to approximately 30–35% of cancer cases (Kushi  et al., 2006 and 
Anand  et al.,  2008). Diets that are low in vegetables, fruits and whole grains, 
and high in processed or red meats are linked with a number of cancers 
(Kushi  et al., 2006). Worldwide approximately 18% of cancers are related 
to infectious diseases (Anand  et al., 2008). Viruses are usual infectious agents 
that cause cancer but bacteria and parasites may also have an effect. A virus 
that can cause cancer is called an oncovirus. Up to 10% of invasive cancers are 
related to radiation exposure, including both ionizing radiation and non-
ionizing radiation (Anand et al., 2008).  
The vast majority of cancers are non-hereditary, which are called sporadic 
cancers. Hereditary cancers are cancers that are primarily caused by an 
inherited genetic defect. Less than 0.3% of the population are carriers of a 
genetic mutation which has a large effect on cancer risk. They cause less than 
3–10% of all cancers (Roukos, 2009).   
Some substances cause cancer primarily through their physical, rather than 
chemical, effects on cells. A prominent example of this is prolonged exposure 
to asbestos, naturally occurring mineral fibers which are a major cause 
of mesothelioma, a type of lung cancer (Maltoni et al., 2000).  Physical trauma 
resulting in cancer is relatively rare. One accepted source is frequent, long-term 
application of hot objects to the body. It is possible that repeated burns on the 
same part of the body, such as those produced by kanger and kairo heaters may 
produce skin cancer, especially if carcinogenic chemicals are also present 
(Gaeta, 2000). Frequently drinking scalding hot tea may produce esophageal 
cancer (Gaeta, 2000). 
Cancer is fundamentally a disease of failure of regulation of tissue growth. In 
order for a normal cell to transform into a cancer cell, the genes which regulate 
cell growth and differentiation must be altered (Croce, 2008). The affected 
genes are divided into two broad categories. Oncogenes  are genes which 
promote cell growth and reproduction. Tumor suppressor genes are genes 
which inhibit cell division and survival. Malignant transformation can occur 
through the formation of novel oncogenes, the inappropriate over-expression of 
normal oncogenes, or by the under-expression or disabling of tumor suppressor 
genes. Typically, changes in many genes are required to transform a normal 
cell into a cancer cell (Knudson 2001). 
Cancer has a reputation as a deadly disease. In 2008 approximately 
12.7 million cancers were diagnosed (excluding non-melanoma skin 
cancers and other non-invasive cancers) and 7.6 million people died of cancer 
worldwide (Jemal et al., 2011). Cancers as a group account for approximately 
13% of all deaths each year with the most common being: lung cancer (1.3 
million deaths), stomach cancer (803,000 deaths), colorectal cancer (639,000 
deaths), liver cancer (610,000 deaths), and breast cancer (519,000 deaths) 
(WHO, 2006). This makes invasive cancer the leading cause of death in 
the developed world and the second leading cause of death in the developing 
world (Jemal et al., 2011). Over half of cases occur in the developing world 
(Jemal, 2011). Cancer is regarded as a disease that must be "fought" to end. 
2.2 Colorectal cancer 
Colorectal cancer, commonly known as bowel cancer, is a cancer caused by 
uncontrolled cell growth (neoplasia) in the colon, rectum, or vermiform 
appendix. Colorectal cancer is clinically distinct from anal cancer, which 
affects the anus. Colorectal cancers start in the lining of the bowel. If left 
untreated, it can grow into the muscle layers underneath, and then through the 
bowel wall. Most begin as a small growth on the bowel wall: a colorectal 
polyp or adenoma. These mushroom-shaped growths are usually benign, but 
some develop into cancer over time. Localized bowel cancer is usually 
diagnosed through colonoscopy. Invasive cancers that are confined within the 
wall of the colon (TNM stages I and II) are often curable with 
surgery. However, if left untreated, the cancer can spread to regional lymph 
nodes (stage III). Cancer that has spread widely around the body (stage IV) is 
usually not curable. Colorectal cancer is the third most commonly diagnosed 
cancer in the world, but it is more common in developed countries 
(http://esa.un.org). Around 60% of cases were diagnosed in the developed 
world (http://globocan.iarc.fr/).  
2.2.1 Symptoms 
The symptoms of colorectal cancer depend on the location of tumor in the 
bowel, and whether it has spread elsewhere in the body (metastasis). While no 
symptom is diagnostic of colorectal cancer, rectal bleeding or anemia are high 
risk features (Astin  et al., 2011). There may be a change in bowel habit (such 
as unusual and unexplained constipation or diarrhea), and a feeling of 
incomplete defecation (rectal tenesmus). Lower gastrointestinal bleeding, 
including the passage of bright red blood in the stool, may indicate colorectal 
cancer, as may the increased presence of mucus. Melena, black stool with a 
tarry appearance, normally occurs in upper gastrointestinal bleeding (such as 
from a duodenal ulcer), but is sometimes encountered in colorectal cancer 
when the disease is located in the beginning of the large bowel. A tumor that is 
large enough to fill the entire lumen of the bowel may cause bowel obstruction. 
This situation is characterized by constipation, abdominal pain, abdominal 
distension and vomiting. This occasionally leads to the obstructed and 
distended bowel perforating and causing peritonitis. A large left colonic tumor 
may compress the left ureter and cause hydronephrosis. Colorectal cancer may 
also lead to weight loss, generally due to appetite. There may be rarer 
symptoms including unexplained fever or thrombosis, usually deep vein 
thrombosis. Such symptoms, known as paraneoplastic syndrome, are due to the 
body's immune response to the cancer, rather than the tumor itself. The lifetime 
risk of developing colon cancer in the United States is about 7%. Certain 
factors increase a person's risk of developing the disease (Levin and Dozois, 
1991). These include: age, polyps of the colon, history of cancer, heredity, 
smoking, physical inactivity, inflammatory bowel disease and environmental 
factors. 
2.2.2 Origin 
Colorectal cancer is a disease originating from the epithelial cells lining the 
colon or rectum of the gastrointestinal tract, most frequently as a result of 
mutations in the Wnt signaling pathway that artificially increase signaling 
activity. The mutations can be inherited or are acquired, and must probably 
occur in the intestinal crypt stem cell (Ionov et al., 1993 and Srikumar et al., 
1999). The most commonly mutated gene in all colorectal cancer is 
the APC gene, which produces the APC protein. The APC protein is a "brake" 
on the accumulation of β-catenin protein; without APC, β-catenin accumulates 
to high levels and translocates (moves) into the nucleus, binds to DNA, and 
activates the transcription of genes that are normally important for stem cell 
renewal and differentiation but when inappropriately expressed at high levels 
can cause cancer. While APC is mutated in most colon cancers, some cancers 
have increased β-catenin because of mutations in β-catenin (CTNNB1) that 
block its degradation, or they have mutation(s) or other genes with function 
analogous to APC such as  AXIN1,  AXIN2,  TCF7L2, or the Naked cuticle 
(Nkd)  gene  NKD1(Markowitz  and  Bertagnolli, 2009). Beyond the defects in 
the Wnt-APC-beta-catenin signaling pathway, other mutations must occur for 
the cell to become cancerous. The p53 protein, produced by the TP53 gene, 
normally monitors cell division and kills cells if they have Wnt pathway 
defects. Eventually, a cell line acquires a mutation in the TP53 gene and 
transforms the tissue from an adenoma into an invasive carcinoma (Markowitz 
and Bertagnolli, 2009).  
Some genes are oncogenes - they are over expressed in colorectal cancer. For 
example, genes encoding the proteins KRAS, RAF and PI3K, which normally 
stimulate the cell to divide in response to growth factors, can acquire mutations 
that result in over-activation of cell proliferation(Vogelstein and Kinzler,  
2004).  
2.2.3 Detection 
Colorectal cancer can take many years to develop and early detection of 
colorectal cancer greatly improves the chances of a cure. Therefore, screening 
for the disease is recommended in individuals who are at increased risk. There 
are several different tests available for this purpose. 
 Digital rectal exam (DRE): The doctor inserts a lubricated, gloved finger 
into the rectum to feel for abnormal areas. It only detects tumors large 
enough to be felt in the distal part of the rectum but is useful as an initial 
screening test. 
 Fecal occult blood test (FOBT): A test for blood in the stool. Two types of 
tests can be used for detecting occult blood in stools i.e. guaiac based 
(chemical test) and immunochemical. The sensitivity of immunochemical 
testing is superior to that of chemical testing without an unacceptable 
reduction in specificity (Weitzel, 1999). 
 M2-PK: A CE marked stool test which indicates colorectal polyps, 
colorectal cancer, acute and chronic inflammatory bowel disease and other 
diseases of the digestive tract. The test result is not affected by any foods, 
so no dietary restrictions are necessary before taking the stool sample. It 
detects bleeding and non-bleeding colorectal polyps and tumors and has 
significantly superior sensitivity compared to conventional occult blood 
tests (Koss et al., 2008). The amount of M2-PK in stool can be quantified 
in 4 mg of feces either by ELISA or with a Point-of-Care Rapid Test. 
 Endoscopy: 
Sigmoidoscopy: A lighted probe (Sigmoidoscope) is inserted into the 
rectum and lower colon to check for polyps and other abnormalities. 
Colonoscopy: A lighted probe called a Colonoscope is inserted into the 
rectum and the entire colon to look for polyps and other abnormalities that 
may be caused by cancer. A colonoscopy has the advantage that 
if polyps are found during the procedure they can be removed immediately. 
Tissue can also be taken for biopsy. 
 Blood tests: Measurement of the patient's blood for elevated levels of 
certain proteins can give an indication of tumor load. In particular, high 
levels of   carcinoembryonic antigen (CEA) in the blood can 
indicate metastasis of adenocarcinoma. These tests are frequently false 
positive or false negative, and are not recommended for screening, it can be 
useful to assess disease recurrence.  
2.2.4 Pathology 
The pathology of the tumor is usually reported from the analysis of tissue taken 
from a biopsy or surgery. A pathology report will usually contain a description 
of cell type and grade. The most common colon cancer cell type 
is adenocarcinoma which accounts for 95% of cases. Other, rarer types 
include lymphoma and squamous cell carcinoma. 
2.2.5 Staging 
Colon cancer staging is an estimate of the amount of penetration of a particular 
cancer. The systems for staging colorectal cancers depend on the extent of 
local invasion, the degree of lymph node involvement and whether there is 
distant metastasis. Definitive staging can only be done after surgery has been 
performed and pathology reports reviewed. An exception to this principle 
would be after a colonoscopic polypectomy of a malignant pedunculated polyp 
with minimal invasion. Preoperative staging of rectal cancers may be done 
with endoscopic ultrasound. The most common staging system is the TNM (for 
tumors/nodes/metastases) system, from the American Joint Committee on 
Cancer (AJCC staging manual, 2002). The TNM system assigns a number 
based on three categories. "T" denotes the degree of invasion of the intestinal 
wall, "N" the degree of lymphatic node involvement, and "M" the degree 
of metastasis. The broader stage of a cancer is usually quoted as a number I, II, 
III, IV derived from the TNM value grouped by prognosis; a higher number 
indicates a more advanced cancer and likely a worse outcome. Details of this 
system are shown in table 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: TNM  system of staging (AJCC staging manual, 2002) 
AJCC stage  TNM stage   (AJCC Cancer Staging Manual, 2002)  
Stage 0 Tis N0 M0 Tis: Tumor confined to mucosa; cancer-in-situ 
Stage I T1 N0 M0 T1: Tumor invades submucosa 
Stage I T2 N0 M0 T2: Tumor invades muscularis propria 
Stage II-A T3 N0 M0 
T3: Tumor invades subserosa or beyond (without 
other organs involved) 
Stage II-B T4 N0 M0 
T4: Tumor invades adjacent organs or perforates 
the visceral peritoneum 
Stage III-A T1-2 N1 M0 
N1: Metastasis to 1 to 3 regional lymph nodes. T1 
or T2. 
Stage III-B T3-4 N1 M0 
N1: Metastasis to 1 to 3 regional lymph nodes. T3 
or T4. 
Stage III-C any T, N2 M0 
N2: Metastasis to 4 or more regional lymph 
nodes. Any T. 
Stage IV any T, any N, M1 M1: Distant metastases present. Any T, any N. 
 
 
 
 
          Fig.1: Endoscopic image of colon cancer identified in 
sigmoid colon on screening colonoscopy  (Source: Wikipedia)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Fig.2: Gross appearance of a colectomy specimen containing  
invasive     colorectal carcinoma   (Source: Wikipedia) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.5.1 Dukes system 
The Dukes classification (Dukes, 1932) is an older and less complicated 
staging system, which predates the TNM system. It identified the stages as: 
 A - Tumour confined to the intestinal wall 
 B - Tumour invading through the intestinal wall 
 C - With lymph node(s) involvement (this is further subdivided into C1 
lymph node involvement where the apical node is not involved and C2 
where the apical lymph node is involved) 
 D - With distant metastasis 
2.2.6 Incidence 
The incidence of colorectal cancer varies greatly between different regions of 
the world, much of it can be attributed to differences in diet, particularly the 
consumption of red and processed meat, fibre and alcohol, as well as 
bodyweight and physical activity (Cancer Stats). Incidence rates of colorectal 
cancer are increasing in countries where rates were previously low (especially 
in Japan, but also in other Asian countries) as diets become more Westernized, 
and either gradually increasing, stabilising (Northern and Western Europe) or 
declining (North America) with time. In 2008, almost 60% of cases were 
diagnosed in the developed world (Cancer Stats). Colorectal cancer (CRC) is 
the third most common cause of cancer-related death in the western world. The 
annual incidence of CRC worldwide has been estimated to be at least half a 
million (Kemp et al., 2004). It is a commonly diagnosed cancer in both men 
and women. In 2008, about 148,810 new cases were diagnosed, and almost 
49,960 deaths from colorectal cancer were speculated (American Cancer 
Society, 2008). A major cause of death in CRC is the development of distant 
metastases through the spreading of tumor cells from the primary tumor site. 
Thus, it is important to find biological markers that can identify CRC patients 
that would benefit from adjuvant treatment due to an increased risk of 
recurrence. It would also be of great value to identify premalignant alterations 
in macroscopically normal-appearing colorectal mucosa that could be used in 
screening tests for patients at risk of developing CRC. 
Kashmir valley located in the northern division of India, surrounded by 
Himalayas has a unique ethnic population living in a temperate environmental 
conditions having distinctive food habits which play an overwhelming role in 
the development of GIT cancers over the genetic factors (Shah  and Jan, 1990; 
Murtaza et al., 2006; Salam  et al., 2009).  The food habits include 
consumption of sun-dried and smoked fish and meat, dried and pickled 
vegetables, red chili, Hakh (a leafy vegetable of Brassica family), hot noon 
chai (salted tea) and Hukka (water pipe) smoke (Mir  et al., 2005). As 
previously reported (Siddiqi   et al., 1992) the etiology and incidence of 
various GIT cancers in this population has been attributed to a probable 
exposure to nitroso compounds, amines and nitrates reported to be present in 
these local food stuffs. Colorectal cancer being the commonest cancer, is the 
major cause of mortality and morbidity worldwide, there are nearly one million 
new cases of colorectal cancer diagnosed world-wide each year and half a 
million deaths (Boyle  and Elena, 2002). The incidence of this malignancy 
shows considerable variation among racially or ethnically defined populations 
in multiracial/ethnic countries. Kashmir has been reported by now as a high-
incidence area of GIT cancers (Shah and Jan, 1990; Mir  et al., 2005; Salam  et 
al., 2009). Colorectal Cancer in Kashmir valley is the third most common GIT 
cancer after esophageal and gastric cancer.  
2.2.7 Causes 
Cancer formation is a multistep process in which defects in a wide range of 
cancer genes accumulate (Balmain et al., 2003). Eventually every cancer 
receives an enormous complexity of altered gene functions, including 
activation of proto-oncogene as well as silencing of genes with tumor-
suppressing function (Ilyas et al., 1999). Genetic alternations including 
mutation, deletion, and DNA amplification have been shown to play an 
important role in tumorigenesis (Ingvarsson, 1999), however, the genetic 
abnormalities found in cancers will not provide the whole picture of genomic 
alternations. 
The development of CRC is a multistep process, which can arise due to the 
cumulative effect of mutations in various different proto-oncogenes, tumor 
suppressor genes, and/or from epigenetic changes in DNA (Vogelstein  et al., 
1988; Fearon et al., 1990; Mustafa et al., 2007). Recent progresses made in the 
field of molecular biology have shed light on the different alternative pathways 
involved in colorectal carcinogenesis, and more importantly on the cross talk 
among these pathways (Risques  et al., 2003; Takayama  et al., 2006). 
2.2.8 Epigenetic mechanism 
Epigenetic mechanisms are used in many different ways for control of gene 
expression. Epigenetic changes never involve a change in the primary DNA 
sequence or a change in base pairing but are reflected primarily in DNA 
cytosine modification patterns, histone post-translational modifications, or 
deposition of certain histone variants along specific gene sequences. These 
epigenetic modifications of genes are generally reversible, but can get 
transmitted to the daughter cells (Laird, 2005). For example, one type of 
epigenetic change that can occur is that the chromatin structure changes from 
an open active configuration, also referred to as euchromatin, to a densely 
packed inactive chromatin structure, the so-called heterochromatin. One 
common and perhaps the most permanent and stable mechanism of epigenetic 
gene inactivation is the methylation of the 5-carbon of the DNA base cytosine 
in the 5′-CpG-3′ dinucleotide sequence context of CpG island of promoter 
regions. These methylation reactions carried out by DNA cytosine 
methyltransferases are a main component of epigenetic regulatory mechanisms 
in mammals (Baylin et al., 2001). Cytosine methylation of DNA at CpG 
dinucleotides is the most well known epigenetic change. Less than 10% of all 
cytosines are methylated in the human genome (Estellier, 2005). These CpG 
dinucleotides are also not found randomly throughout the genome, but in finite 
areas, specifically clustered at the 5' region of genes, in the promoter, 
untranslated region and exon 1. These CpG islands are not methylated in 
normal cells, thereby allowing for transcription of the genes through allowing 
access of the transcription machinery to the DNA. However, in cancer cells, 
these CpG dinucleotides found within these CpG islands is targeted and 
hypermethylated, thereby preventing any transcription activators to access the 
DNA. This is known as silencing, and often occurs on tumour-suppressor 
genes leading to tumorigenesis. Tumor-suppressor genes have an open 
chromatin conformation, with promoter CpG island hypomethylation. CpG 
island hypermethylation closes the chromatin conformation through 
condensation and packaging, thereby allowing the cell entry in the cycle 
without regulation, and avoidance of cell death. Interestingly, in tumor cells, 
gene-specific 5' region CpG's are highly methylated, while the rest of the 
genome becomes highly unmethylated. This may be due to repetitive 
sequences and genome stability, and tumor cells exhibit genome fragility and 
chromatin instability. 
Tumor suppressor genes were initially hypothesized to be inactivated in cancer 
cells as a result of genetic defects of both alleles (i.e., the Knudson two-hit 
hypothesis). However, there is now evidence that epigenetic events, such as 
hypermethylation of cytosine–guanine (CpG) sites in regulatory regions (e.g., 
the promoter), may be a critical alternative mechanism of tumor suppressor 
gene inactivation. In tumor tissues, tumor suppressor genes are often 
inactivated epigenetically by methylation when compared with normal tissue. 
The DNA methylation events are often preceded by changes in chromatin 
structure and histone modifications. 
Epigenetic alternations of the DNA such as methylation of CpG island in 
promoter region or histone modification donot alter sequence code. Instead, 
they participate in the regulation of gene expression that is now recognized as 
an additional method to be involved in tumorigenesis (Plass, 2002; Jaenisch 
and Bird, 2003; Nephew and Huang, 2003). Methylation of cytosine residue at 
CpG dinucleotides in mammalian genomes is found to have significant effect 
on gene expression (Baylin and Herman, 2000; Ehrlich, 2002). In higher order 
eukaryotes, DNA is methylated only at cytosines located 5' to guanosine in the 
CpG dinucleotide (Holliday and Grigg, 1993). This modification has important 
regulatory effects on gene expression, especially when involving CpG-rich 
areas known as CpG islands, located in the promoter regions of many genes 
(Bird, 1986; 1992). While almost all gene-associated islands are protected from 
methylation on autosomal chromosomes (Bird, 1986), extensive methylation of 
CpG islands has been associated with transcriptional inactivation of selected 
imprinted genes ( Li  et al., 1993;  Tremblay  et al., 1995)  and genes on the 
inactive X-chromosome of females (Pfeifer  et al., 1989;Riggs  et al., 1992). 
Aberrant methylation of normally unmethylated CpG islands has been 
documented as a relatively frequent event in immortalized and transformed 
cells (Antequera et al., 1990) and has been associated with transcriptional 
inactivation of defined tumor suppressor genes in human cancers (Herman et 
al., 1994; Merlo et al., 1995; Graff et al., 1995; Herman et al., 1996). In this 
situation, promoter region hypermethylation stands as an alternative to coding 
region mutations in eliminating tumor suppressor gene function (Herman et al., 
1994, Merlo et al., 1995). Therefore, mapping of methylation patterns in CpG 
islands has become an important tool for understanding both normal and 
pathologic gene expression events. 
2.2.9 P16 gene 
P16 plays an important role in regulating the cell cycle, and mutations in p16 
increase the risk of developing a variety of cancers, notably melanoma. The 
p16 protein is encoded by the CDKN2 gene. The p16 (CDKN2a/INK4a) gene is 
an important tumor-suppressor gene, involved in the p16/cyclin-dependent 
kinase/retinoblastoma gene pathway of cell cycle control, in which the p16 
protein is considered to be a negative regulator involved in the inhibition of G1 
phase progression (Rocco et al.,  2001). P16 gene is located on human 
chromosome 9 with location 9P21 and is of length 8.5Kb. The complete p16 
memory is by two introns and three exons, coding a known cyclin-dependent 
kinase CDK4 inhibitor protein. 
The molecular weight of it is 15.8kd and is referred to as P16.The human p16 
protein contains 156 amino acids and was first discovered in a yeast two-hybrid 
system to detect proteins that interact with human cyclin-dependent kinase 
(Ruas and Peters, 1998). The tumor-suppressor function of p16 is attributed to 
its ability to inhibit the catalytic activity of the cyclin-dependent kinase 4-
6/cyclin D complex that is required for phosphorylation of retinoblastoma 
protein (Serrano et al., 1993; 1996). Dephosphorylated Rb protein-binding 
transcription factors (such as the EIF) can not be released activation. The cells 
get arrested in G0 phase or G1 phase, while inhibiting cell division and 
proliferation. P16 gene abnormal changes lead to the loss of the negative 
regulation of cell growth. CDK4 and cyclin D1 binding to Rb protein  lead to 
its phosphorylation and in the release of a large number of transcription factors 
which change G1 phase cells into S phase cells rapidly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
                   
Fig.3:  Chromosomal location of P16 gene.    (Source: Pubmed) 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.10 Inactivation of p16 gene 
Inactivation of p16 gene plays an important role not only in tumorigenesis but 
is also considered to be a poor prognostic event in certain malignancies 
(Serrano  et al., 1993; Serrano et al., 1996; Ruas and Peters, 1998; Rocco  et 
al., 2001). DNA methylation is a frequent mechanism of transcriptional 
silencing in human cancer (Herman et al., 2000). Recently, aberrant 
methylation of multiple promoter-associated CpG islands of tumor-suppressor 
genes has been found in a variety of human malignancies. Promoter 
hypermethylation, in addition to gene deletion and point mutation of p16 locus, 
has been found to be one of the main mechanisms of p16 inactivation (Cairns  
et al., 1995). Hypermethylation of the 5'CpG islands of p16 gene promotor 
region has been reported in colon, bladder, breast, head and neck, and lung 
carcinoma as well as in glioma, melanoma, leukemia and lymphoma 
(Reznikoff  et al., 1996). However, there appears to be evidence supporting a 
role for p16 inactivation in the transformation of low-growth fraction 
lymphomas into their aggressive variants (Navas et al., 2002). The histological 
progression of follicular lymphoma to aggressive large-cell lymphoma is 
frequently accompanied by 9p21 deletions that often result in reduction or loss 
of p16 expression. In mantle cell lymphoma, p16 deletions are associated with 
aggressive forms, a finding that suggests the possibility that cyclin D1 
overexpression and p16 inactivation might not be completely redundant 
alterations (Sanchez-Beato et al., 2003). Mechanisms of p16 silencing include 
loss of heterozygosity, homozygous deletion, point mutation and promoter 
region hypermethylation. The latter appears to be a major reason 
for p16 inactivation in many previous studies. There appears to be good 
agreement of p16 promoter methylation with lack of protein expression in B-
cell lymphomas (Sanchez-Beato  et al., 2001; 2003). 
Hypermethylation of the p16 tumour suppressor gene and subsequent 
transcriptional silencing has been implicated as an additional mechanism of 
p16 gene inactivation in diverse types of cancer including gastric cancer, lung 
cancer, colon cancer, thyroid carcinoma, and hepatic carcinoma (Elisei  et al.,  
1998; Gazzeri et al.,  1998; Shim et al., 2000; 2003; Ding  et al., 2003). 
Methylation of p16 gene correlated with decrease expression in human gastric 
cancer (Shim et al., 2000) and hypermethylation of p16 occurs in the early 
stage of hepatic cell carcinomas and is associated with hepatitis B virus 
infection (Shim et al., 2003). Promoter hypermethylation of several tumor 
suppressor genes such as p16, p15, E-cadherin were also found in different 
type of leukemias (Gutierrez et al., 2003; Galm et al., 2004). The relationship 
of p16 inactivation or aberrant genetic or epigenetic changes of the p16 gene 
with tumor progression or patient survival has been investigated in various 
forms of human tumor, such as breast cancer (Child  et al.,  2002), cutaneous 
melanoma (Straume  and Akslen, 1997), colorectal carcinoma (Esteller et al., 
2001), central nervous system malignancies (Straume et al.,  2000), lung 
cancer (Kim et al.,  2001) and head and neck carcinoma (Bova et al., 1999) 
with no general consensus. However, before accepting the conclusion that 
hypermethylation of tumor suppressor gene promoters is invariably the cause 
of gene inactivation, it is worth evaluating the data a bit more critically. 
Epigenetic mechanisms of gene inactivation, including promoter 
hypermethylation, are undoubtedly important in cancer development and 
represent an alternative means of inactivating tumor suppressor genes. 
Nevertheless, the standard of proof for establishing that hypermethylation of 
the promoter of any given gene has a critical role in loss of gene expression 
and cancer development should probably be set quite high, regardless of 
whether the gene is a well-established tumor suppressor gene, like p16, or a 
potential tumor suppressor gene. Evidence might include data indicating that 
the methylation status of a promoter is tightly linked to its expression in a large 
panel of primary cancer specimens and data showing that gene expression can 
be readily and fully restored by treatment of cancer cells with demethylating 
agents, it is worth bearing in mind that, in some cases, promoter 
hypermethylation may be a reflection rather than a cause of gene inactivation 
in cancer.  In this study, the aberrant promoter hypermethylation of p16 gene in 
colorectal cancer was demonstrated. The result suggested that promoter 
methylation of this gene plays an important role in colorectal tumorigenesis. 
 
 
 
Materials and Method: 
The study was a hospital based case control study undertaken to understand the 
etiology of colorectal cancer in Kashmir valley-a north Indian state with high 
incidence rate of this dreadful disease. The research work was initiated 
following approval by the Board of Research Studies (BORS) of the University 
of Kashmir. All ethical considerations were taken care of during the study and 
the recruitment process was started only after ethical clearance from the 
Departmental Ethical Committee as per norms.  Subjects with 
histopathologically and endoscopically confirmed colorectal carcinoma were 
evaluated. The colorectal carcinoma samples were collected from the 
Department of Surgery, Government S.M.H.S (Shri Maharaja Hari Singh) 
Hospital associated with Government Medical College, Srinagar either by 
means of surgical resection or endoscopically. Histopathologically confirmed 
normal were taken as controls. The study included 70 surgically obtained 
colorectal samples among which 50 were obtained from colorectal cancer 
patients and 20 were histopathologically normal colorectal samples. All the 
samples were histopathologically confirmed before further processing. Record 
was maintained of the complete case history of the patients. The various 
methods that were used to analyse the epigenetic silencing of tumour 
suppressor gene p16 by promoter hypermethylation at CpG islands as a part of 
this study are described under: 
3.1. CASES 
All the colorectal cancer patients that were operated in the Department of 
Surgery, Government S.M.H.S Hospital, Srinagar during the study period were 
included in the study irrespective of their age, gender and stage of the cancer. 
3.1.1. Inclusion criteria 
The diagnosis of colorectal cancer was based on the standard histopathological 
criteria. The criteria for including a subject as case in the study were: 
 All histopathologically confirmed patients irrespective of cancer stage, 
age, gender. 
 Native patients belonging to Kashmir valley. 
3.1.2. Exclusion Criteria 
Under the following conditions the patients were not recruited in the study: 
 Patients who had received prior chemo or radiotherapy. 
 Patients not belonging to Kashmir valley. 
 Patients with genetic disorders like HNPCC/ APC. 
 Patients who suffered from any other kind of malignancy 
3.2. CONTROLS 
Resected colorectal samples from Department of Surgery, S.M.H.S Hospital 
including colorectal biopsies from Endoscopic section of S.M.H.S Hospital 
which were histopathologically confirmed as normal were taken as controls. 
 3.2.1. Inclusion criteria 
 Native populace of the Kashmir valley. 
3.2.2. Exclusion criteria  
 Patients who suffered from any other kind of malignancy. 
 Patients not of Kashmiri origin. 
3.3. COLLECTION OF TISSUE SAMPLES 
The carcinoma and control samples were obtained from the Department of 
Surgery and Endoscopic Section of Government S.M.H.S Hospital and were 
put in sterilized plastic vials (50 ml volume) containing 10 ml of normal saline 
and transported from the theatres to the laboratory on ice and stored at -80
 o
 C 
for further analysis. The vials were properly labelled according to a specially 
designed coding system. This coding system was developed so as to prevent 
possible mixing of the sample vials and for easy retrieval of the required 
sample vial. Also, a part of each sample was sent to histopathology laboratory 
of S.M.H.S hospital for histopathological confirmation. The information 
regarding the gender, stage and histological grade for each carcinoma sample 
was collected from the histopathological reports. The information regarding the 
gender of control samples was also collected.  
3.4. GENETIC ANALYSIS 
 3.4.1. Extraction of genomic DNA 
For the isolation of genomic DNA, kit based method was used. The kit used 
was Quick- g DNA
TM
 MiniPrep supplied by ZYMO RESEARCH. The 
protocol followed was as per kit.  
 25 to 50 mg of tissue was taken and the cells were mechanically 
homogenised in 500 µl genomic lysis buffer (provided in the kit). 
 The lyaste was centrifuged at 10,000 X g for 5 min. and the supernatant 
transferred to Zymo-Spin
TM
 column in a collection tube and again 
centrifuged at 10,000 X g for 1 min.  
 Flow through along with the collection tube was discarded and the 
zymo-spin
TM
 column transferred to a new collection tube and 200 µl of 
DNA pre-wash buffer (provided in the kit) added to the tube and 
centrifuged at 10,000 X g for 1 min., followed by the addition of 500 µl 
of g- DNA wash buffer to the Zymo-Spin
TM
 column and again 
centrifuged at 10,000 X g for 1 min.  
 The spin column was transferred to a clean micro centrifuge tube and 
DNA was eluted from it into the micro centrifuge tube by addition of 
50 µl of DNA elution buffer (provided in the kit). 
The DNA eluted was stored at 4
0
C for a short time but the vials were kept at -
20
o
C for longer duration storage for further investigation. 
3.4.2. QUALITATIVE AND QUANTITATIVE ANALYSIS OF 
GENOMIC DNA  
3.4.2.1. Qualitative Analysis 
The integrity of the genomic DNA was examined by gel electrophoresis using 
1 % agarose gel. 2µl of each DNA sample was mixed with 1µl of 1X DNA 
loading dye (1X loading dye consists of 4.16 mg bromophenol blue, 4.16 mg 
xylene cyanol and 0.66g sucrose in1ml water) and was loaded in the gel. 
Electric current was applied at 50 volt until DNA entered in to the gel and was 
increased to 70 volt for rest of the run. Electrophoresis was stopped when the 
dye had travelled nearly 2/3rd of the gel. DNA in the gel was visualized with 
the help of Gel doc system (AlphaimagerTM 2200, Alpha Innotech 
Corporation) under UV light and picture was captured by using CCD camera 
system. 
3.4.2.2. Quantitative Analysis 
The quantity of the DNA was determined by measuring optical density at 
260nm and 280 nm by double beam spectrophotometer (Evolution 60S from 
Thermo Scientific) and the concentration was determined by using the fact that 
absorbance of 1 unit equates to 50µg of DNA/ cm
3
 and therefore, the 
concentration of DNA sample is given by the following equation 
DNA (µg/ml) = A260 x 50 x dilution factor 
 The ratio of 260/280nm was calculated and the DNA samples for which the 
ratio was 1.7-1.9 were considered for the future use. DNA was alliqouted into 
three to four tubes so as to protect damage from freeze thawing and stored in -
20
o
C freezer for longer duration of time. 
3.5. DNA MODIFICATION (BISULFITE TREATMENT) 
Sodium bisulfite treatment converted unmethylated cytosines to uracil and 
hence enabled to distinguish between the hypermethylated and non 
hypermethylated cytosine residues. DNA was modified by kit based method, 
the kit used was EZ DNA Methylation
TM
 Kit (The kit has > 99% conversion 
efficiency of converting non-methylated C residues into U, and the modified 
DNA recovery from the kit is > 80%). The protocol supplied with the kit was 
followed. 
  500-1000 ng of above isolated DNA samples were taken in different 
eppendorf tubes. 
 To each tube 5 µl of M-Dilution Buffer provided in the kit was added 
and final volume made to 50 µl with distilled water. 
 Then to each tube 100 µl CT-conversion reagent provided in the kit was 
added and all the tubes were kept in dark at 50
o
C-55
o
C for 12-16 hrs. 
 After that all samples were placed on ice for 5-10 mins. 
 400 µl of M-binding buffer provided in the kit was added to zymo-
spin
TM
 IC columns provided in the kit and and the columns were placed 
into provided Collection Tubes. 
 Sample (from step 4) were loaded into zymo-spinTM IC columns which 
contained M-binding buffer. The caps were closed and the solution 
mixed by inverting columns several times. 
 Then columns were centrifuged at full speed (≥10,000× g) for 30 
seconds and the flow-through discarded. 
 100 µl of M-wash buffer provided in the kit was added to these 
columns and then centrifuged at full speed for 30 seconds and the flow-
through again discarded. 
 200 µl of M-desulphonation buffer provided in the kit was added to 
each column and then kept at room temperature (20
0
C-30
0
C) for 15-20 
minutes. After the incubation, the columns were centrifuged at full 
speed for 30 seconds and   the flow-through discarded. 
 200 µl of M-wash buffer was added to each column and then 
centrifuged at full speed for 30 seconds. Again 200 µl of M-wash buffer 
was added to each column and then centrifuged for an additional 30 
seconds. The flow-through discarded each time. 
 The columns were placed into 1.5 ml micro centrifuge tubes and 15 µl 
of M-elution buffer provided in the kit was directly added to each 
column matrix. Then these columns were centrifuged for 30 seconds at 
full speed and the DNA eluted. 
The modified DNA was stored at -20
0
C for further use. 
 
3.6. METHYL SPECFIC POLYMERASE CHAIN REACTION 
(MSP)  
To determine the status of p16 promoter methylation in colorectal cases from 
Kashmir valley, we performed Methyl specific PCR (MSP) for the promoter 
region of p16 gene in 50 surgically resected colorectal cancer DNA and 
compared with that of 20 histopathologically confirmed normal colorectal 
tissues. MSP is a novel and sensitive way for detection of hypermethylation in 
CpG islands of DNA (Herman et al., 1996).  The sensitivity of MSP suggests it 
would be useful for primary tumours as well, allowing for detection of 
aberrantly methylated alleles even if they contribute relatively little to the 
overall DNA in a sample. 
The principle of this PCR method lies in the amplification of the 
hypermethylated and non-methylated DNA of the same gene by different 
primer sequence; one for hypermethylated version of the gene and one for the 
non-methylated version of the same gene. Thus by visualising the PCR product 
we can easily determine whether amplification is by methylated or non-
methylated primers, thus determine whether CpG’s were hypermethylated or 
non hypermethylated.  
Primers described previously by Herman et al., 1996 were used to discriminate 
between methylated and unmethylated DNA following bisulfite treatment and 
to discriminate between DNA modified by bisulfite and that which had not 
been modified. To accomplish this, primer sequences has been chosen for 
regions containing frequent cytosines (to distinguish unmodified from modified 
DNA), and CpG pairs near the 3' end of the primers (to provide maximal 
discrimination in the PCR between methylated and unmethylated DNA). The 
fragment of DNA to be amplified was intentionally small, to allow the 
assessment of methylation patterns in a limited region and to facilitate the 
application of this technique to samples where amplification of larger 
fragments is not possible. In Table 2, primer sequences and amplicon size are 
shown for gene tested, emphasizing the differences in sequence between the 
types of DNA that are exploited for the specificity of MSP. The multiple 
mismatches in these primers, which are specific for these different types of 
DNA, suggest that each primer set should provide amplification only from the 
intended template. 
 
 
 
 
 
 
 Table 2: Primers (described by Herman et al, 1996) used and length of 
fragments obtained in MSP (Methylation Specific PCR) 
Nature of  
Primer 
Primer sequence Size of 
Amplicon 
 
 
UNMETHYLATED 
PRIMER 
 
Forward 
primer 
 
5′-
TTATTAGAGGGTGGGGTGGATT
GT-3′ 
 
  
      151bp  
Reverse 
primer 
5′-
CAACCCCAAACCACAACCATAA-
3′ 
 
 
METHYLATED 
PRIMER 
 
Forward 
primer 
 
5′-
TTATTAGAGGGTGGGGCGGATC
GC-3′ 
 
  
     150bp   
Reverse 
primer 
5′-
GACCCCGAACCGCGACCGTAA-3′ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
As described earlier PCR was carried out using methyl specific PCR (MSP) 
method. The modified DNA was taken into two PCR vials in equal quantity 
and same amount of all reagents (Table 3) was added to both the vials except in 
one vial where methylated primers were added and in other vial where non-
methylated primers were added. 
PCR amplification was achieved using a Thermal cycler (Gradient thermal 
cycler from EPPENDORF MASTERCYCLER PRO). Reactions were hot-
started at 95
o
C for 5 min, followed by addition of Taq. Polymerase, followed 
by 35 cycles of melting (95
o
C for 30 sec.), annealing (60
0
C/65
0
C for  30 sec.) 
and extension (72
o
C for  30 sec.) and by final extension step at 72
o
C for 4 min 
(Table 4). The annealing temperatures for unmethylated and methylated p16 
amplification was  60
0
C and 65
0
C, respectively. 
Controls without DNA were performed for each set of PCRs. Universal 
Methylated Human DNA Standard and Control with primers was used as 
positive control, and Lymphocyte DNA was used as negative control. 
After amplification each PCR product (10 μl) was directly loaded onto non 
denaturing 2% agarose gel, stained with ethidium bromide, and visualized 
under UV illumination. 
The amplified DNA were of different base pairs in length the methylated band 
was 150 bp and the unmethylated band was 151 bp and this small difference in 
the size of the amplified DNA did not allowed them to be visually 
differentiated in presence of a 100 bp DNA ladder run parallel to the amplified 
PCR products on 2% ethidium bormide pre-loaded agarose gel. 
 
 
 
 
 
 
 
 
 
 
Table 3: Volume and concentrations of different reagents used in PCR 
 
 Reagent 
 
Volume 
1 X Taq buffer 2.5 µl 
dNTPs (1.25mM/ L) 1.25 µl 
Forward primer (150 ng/ reaction) 1µl 
Reverse primer (150 ng/ reaction) 1 µl 
Template DNA(50 ng/ reaction) 1.25 µl 
Taq DNA Polymerase( 5U/ µl ) 0.2 µl 
De ionised water 17.8 µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4: Thermal cycling conditions 
Note: The annealing temperatures for unmethylated and methylated p16 
amplification was  60
0
C and 65
0
C, respectively.  
Steps 
 
Temperature 
0
C Time
 
  Number of 
cycles 
1. Hot-Start 95 5 min 1 
2.  Denaturation 95 30 sec  
35 3. Annealing 60/65 30 sec 
4. Extension 72 30 sec 
5. Final extension 72 4 min 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7. STATISTICAL ANALYSIS 
The χ2-test with Odds ratio was used to examine the differences in the 
distribution of p16 gene promoter hypermethylation and non hypermethylation 
between cases and controls and Fishers exact test was used in case of studying 
the male and female groups as cell frequency was less than 5 in some cells.  
ORs with 95% CIs were computed using unconditional logistic regression 
using Graph Pad Prism Software Version 5.0 by Graph Pad Software 2236, 
Avenida de la Playa, La Jolla, CA 92037, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results: 
4.1.1. Cases 
50 histopathologically confirmed cancer cases were taken. Out of 50 cases 29 
were males which correspond to 58% and hence 21 cases out of 50 were 
females which correspond to 42%. All the patients were symptomatic at the 
time of diagnosis. Of all the ten districts highest number of colorectal cases 
turned out from Srinagar and Budgam districts of Kashmir.  
4.1.2. Controls 
20 histopathologically confirmed normal colorectal tissues were taken as 
controls. Out of 20 normal cases 10 were males which correspond to 50% and 
hence 10 cases out of 20 were females which correspond to 50%. 
4.1.3. Extraction of genomic DNA 
Genomic DNA was isolated by kit based method. The kit used was Quick- g 
DNA
TM
 MiniPrep supplied by ZYMO RESEARCH. Genomic DNA was 
successfully isolated from all 70(50 cases and 20 controls) tissue samples. 
4.1.4. Qualitative analysis  
The integrity of the genomic DNA isolated from tissue samples was 
examined on 1 % agarose gel. The representative gel picture of the isolated 
genomic DNA is given in the figure 4. 
4.1.5. Quantitative Analysis 
The quantity of the DNA was determined by measuring optical density at 
260nm and 280 nm by double beam spectrophotometer (Evolution 60S from 
Thermo Scientific) and the concentration was determined using equation 
DNA (µg/ml) = A260 x 50 x dilution factor 
All 70 tissue samples (50 cases and 20 controls) included in the study were 
found to have the ratio of 260/280nm in the range of 1.7-1.9. 
   
  
Fig.4: Representative gel picture showing the integrity of the genomic DNA 
 on 1.0 % agarose gel. 
 Lane 1 to 8 contains the genomic DNA isolated from the tissue   
 samples of colorectal cancer cases CRC 1 to CRC 8. 
 
 
 
 
 
 
 
 
 
 
 
 4.2. ANALYSIS OF P16 GENE PROMOTER HYPERMETHYLATION 
IN CASES AND CONTROLS 
To determine the status of p16 promoter methylation in colorectal cases from 
Kashmir valley, we performed Methyl specific PCR (MSP) for the promoter 
region of p16 gene in 50 surgically resected colorectal cancer DNA and 
compared with that of 20 histopathologically confirmed normal colorectal 
tissues. Primers described previously by Herman et al., 1996 were used to 
discriminate between methylated and unmethylated DNA following bisulfite 
treatment and to discriminate between DNA modified by bisulfite and that 
which had not been modified. The amplicons were analysed on 2% agarose gel. 
Amplification was carried out using Hot Start PCR method; the method 
involves heating the PCR mixture without Taq Polymerase upto 95
o
C for 5 
min. and then adding Taq Polymerase to it. This decreases the non specific 
amplifications.  
As shown in Table 5 and Fig. 5, 66% (33/50) of the colorectal cancer tissues 
showed methylated p16 promoter and 34% (17/50) of the cases however 
showed unmethylated p16 promoter. Fig. 6 represented few cases among which 
CRC 1 and CRC 4 were found to be methylated and CRC 8 was unmethylated. 
Similarly Fig. 7 represented few cases among which CRC 38 was methylated 
and CRC 23 was unmethylated. Among the methylated cases few cases also 
showed the presence of a band of unmethylated DNA as represented in Fig. 7 
by CRC 13, that could be derived from unmethylated DNA of normal, 
adjoining mucosal cells and tumor cells as well as normal constituents in the 
stroma such as vascular endothelial cells, smooth muscles, fibroblasts and 
inflammatory cells. Almost all 80% (16/20) of the histopathologically 
confirmed normal tissues showed unmethylated p16 promoter except only in 
four cases where p16 promoter was found to be methylated (Table 6 and Fig. 
5). Fig. 8 represented few cases of normal samples like N3, N9 and N17 which 
showed unmethylated p16 promoter. The association of promoter 
hypermethylation with colorectal cancer was evaluated by χ2 (Chi square) test 
with Odds ratio and was found to be significant (P=0.0006, Odds ratio=7.765, 
95% C.I=2.242 to 26.90). 
Table 5: Data representing no. of cases showing promoter 
hypermethylation and non-hypermethylation during MSP amplification in 
colorectal cancer cases confirmed by 2% agarose gel electrophoresis 
CASES (50) 
 PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 33 66 % (33/50) 
NON 
HYPERMETHYLATED 
17 34 % (17/50) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Data representing no. of cases showing promoter 
hypermethylation and non-hypermethylation during MSP amplification in 
histopathologically confirmed normal cases confirmed by 2% agarose gel 
electrophoresis 
CONTROL (20) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 4 20 % (4/20) 
NON 
HYPERMETHYLATED 
16  80% (16/20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5:  Histogram representing hypermethylated and nonhypermethylated cases 
of  colorectal cancer and histopathologically confirmed normal controls 
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       Figure 6. Representing MSP (Methylation Specific PCR) of colorectal 
cancer DNA     samples run on 2% agarose gel 
       Lane 1 and 2-Represents positive control (universal methylated DNA) 
amplified with only methylated primer  
       Lane 3 and 4- Represents CRC1 amplified with only methylated primer 
       Lane 5 and 6- Represents CRC4 amplified with only methylated primer       
Lane 7 and 8- Represents CRC8 amplified with only unmethylated primer  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
      Figure 7. Representing MSP (Methylation Specific PCR) of colorectal 
cancer DNA samples run on 2% agarose gel 
       Lane 1 and 2-Represents positive control (universal methylated DNA) 
amplified with only methylated  
       Lane 3 and 4- Represents CRC13 amplified both with methylated primer 
and unmethylated primer 
       Lane 5 and 6- Represents CRC23 amplified with only unmethylated 
primer       Lane 7 and 8- Represents CRC38 amplified with only 
methylated primer  
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
     
 
 
       Figure 8. Representing MSP (Methylation Specific PCR) of 
histopathologically confirmed normal colorectal DNA samples run on 
2% agarose gel 
       Lane 1 and 2-Represents negative control (lymphocyte DNA which is 
unmethylated) amplified with only unmethylated primer 
       Lane 3 and 4- Represents normal (N3) amplified with only unmethylated 
primer 
       Lane 5 and 6- Represents normal (N9) amplified with only unmethylated 
primer  
       Lane 7 and 8- Represents normal (N17) amplified with only unmethylated 
primer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Relationship between promoter hypermethylation of p16 gene and 
selected clinicopathological parameters 
The relationship between the promoter hypermethylation of p16 gene and 
selected clinicopathological parameters was examined. These parameters 
included gender, clinical staging and histological grade.  
4.3.1. Relationship of promoter hypermethylation of p16 gene in males and 
females  
Occurrence of p16 methylation was found to be unequally distributed in males 
and females with more frequency in males than in females. Among 29 males, 
20 cases were hypermethylated and 9 cases were unhypermethylated and 
among 10 male controls, 2 cases were hypermethylated and 8 cases were 
unhypermethylated (Table 7 and Fig. 9). The association of promoter 
hypermethylation with colorectal cancer was evaluated using Fisher’s exact 
test and was found to be significant in males (P =0.0107, Odds ratio=8.889 and 
95% C.I=1.563 to 50.55). In comparison, among 21 females, 13 cases were 
hypermethylated and 8 cases were unhypermethylated and among 10 female 
controls 1 case was hypermethylated and 9 cases were unhypermethylated 
(Table 8 and Fig.10). The association of promoter hypermethylation with 
colorectal cancer was again evaluated using Fisher’s exact test and was found 
to be significant in females too (P =0.0089,Odds ratio=14.63 and 95% 
C.I=1.547 to 138.3). However, on comparing the male cases with female cases, 
20 cases were hypermethylated and 9 cases were unhypermethylated in males 
and 13 cases were hypermethylated and 8 cases were unhypermethylated in 
females (Table 9 and Fig.11), occurrence of p16 methylation was found to be 
unequally distributed in males and females with more frequency in males than 
in females but the difference was not statistically significant (P =0.7635, Odds 
ratio=1.368 and 95% C.I=0.4197 to 4.456). 
 
 
 
  
 
 
 
 
Table 7: Data representing no. of cases showing promoter 
hypermethylation and non-hypermethylation in male colorectal cancer 
cases and male controls during MSP amplification confirmed by 2% 
agarose gel electrophoresis 
MALE CASES (29) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 20 68.97% (20/29) 
NON 
HYPERMETHYLATED 
9 31.03% (9/29) 
                                              MALES CONTROLS (10) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 2 20 % (2/10) 
NON 
HYPERMETHYLATED 
8 80 % (2/10) 
 
 
 
 
  
 
 
 
 
Fig.9:  Histogram representing hypermethylated and nonhypermethylated male 
 colorectal cancer cases and histopathologically confirmed normal male 
 cases 
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Table 8: Representing no. of cases showing promoter hypermethylation 
and non-hypermethylation in female colorectal cancer cases and female 
controls during MSP amplification confirmed by 2% agarose gel 
electrophoresis 
FEMALE CASES (21) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 13 61.90 % (13/21) 
NON 
HYPERMETHYLATED 
8 38.09 % (8/21) 
                                             FEMALE CONTROLS (10) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 1 10 % (1/10) 
NON 
HYPERMETHYLATED 
9 90 % (9/10) 
 
 
 
 
 
 
 
 
 
Fig.10:  Histogram representing hypermethylated and nonhypermethylated 
female  colorectal cancer cases and histopathologically confirmed normal 
female  cases 
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Table 9: Representing no. of cases showing promoter hypermethylation 
and non-hypermethylation in male and female colorectal cancer patients 
during MSP amplification confirmed by 2% agarose gel electrophoresis 
TOTAL CASES (50) 
MALES (29) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 20 68.97% (20/29) 
NON 
HYPERMETHYLATED 
9 31.03% (9/29) 
 FEMALES (21) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 13 61.90 % (13/21) 
NON 
HYPERMETHYLATED 
8 38.09 % (8/21) 
 
 
 
 
 
 
 
 
Fig.11: Histogram representing hypermethylated and nonhypermethylated 
male   and female histopathologically confirmed colorectal cancer 
cases 
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 4.3.2. Relationship of promoter hypermethylation of p16 gene in Stage I/ II 
and Stage III/IV 
There were 32 cases who were in Stage I and Stage II of the disease. Among 
these cases 18 cases were hypermethylated and 14 cases were 
nonhypermethylated. However, among 18 cases who were in Stage III and 
Stage IV of the disease, 15 cases were hypermethylated and 3 cases were 
nonhypermethylated (Table 10 and Fig.12). When the frequency of p16 
promoter hypermethylation was compared with clinical staging of the disease, 
p16 promoter hypermethylation was found to be certainly higher in Stage 
III/IV (83.33%) compared to Stage I/ II (56.25%) (Table 10 and Fig.12) but the 
difference was not statistically significant (P =0.0673, Odds ratio=3.889 and 
95% C.I=0.9370 to 16.14) (Fisher’s exact test).  
4.3.3. Relationship of promoter hypermethylation of p16 gene and 
histological grade 
The frequency of p16 methylation was 54.54% (6/11) in well differentiated 
adenocarcinoma (WDAC), 67.74% (21/31) in moderately differentiated 
adenocarcinoma (MDAC) and 75% (6/8) in poorly differentiated 
adenocarcinoma (PDAC) (Table 11 and Fig.13). So, the degree of p16 
promoter hypermethylation increased with the increasing severity of the lesion 
but the difference was not again statistically significant (P =0.6145) (Chi 
square test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10: Representing no. of cases showing promoter hypermethylation 
and non-hypermethylation in stage I/II and stage III/IV during MSP 
amplification  confirmed by 2% agarose gel electrophoresis 
TOTAL CASES (50) 
STAGE I/II (32) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 18 56.25 % (18/32) 
NON 
HYPERMETHYLATED 
14  43.75% (14/32) 
 STAGE III/IV (18) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 15 83.33 % (15/18) 
NON 
HYPERMETHYLATED 
3  16.66% (3/18) 
 
 
 
 
 
 
 
 Fig.12: Histogram representing hypermethylated and nonhypermethylated 
cases of  Stage I/II and Stage III/IV  
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Table 11: Representing no. of cases showing promoter hypermethylation 
and non-hypermethylation in well differentiated, moderately 
differentiated and poorly differentiated cases during MSP amplification 
confirmed by 2% agarose gel electrophoresis 
TOTAL CASES (50) 
WELL DIFFERENTIATED(11) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 6 54.54 % (6/11) 
NON 
HYPERMETHYLATED 
5  45.45% (5/11) 
                                      MODERATLY DIFFERENTIATED(31) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 21 67.74 % (21/31) 
NON 
HYPERMETHYLATED 
10 32.25 % (10/31) 
                                       POORLY DIFFERENTIATED(8) 
PARAMETER CASES FREQUENCY 
HYPERMETHYLATED 6 75 % (6/8) 
NON 
HYPERMETHYLATED 
2  25% (2/8) 
 
 
 
 
 
 
 Fig.13: Histogram representing hypermethylated and nonhypermethylated 
cases of  well differentiated, moderately differentiated and poorly 
differentiated  adenocarcinoma 
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Discussion : 
Colorectal cancer (CRC), commonly known as bowel cancer is the third most 
common cause of cancer-related deaths in the western world. Colorectal cancer 
is one of the most aggressive malignancies and occurs at a high incidence in 
most countries (Greenlee et al., 2000). The annual incidence of CRC 
worldwide has been estimated to be at least half a million (Kemp et al., 2004). 
It is a commonly diagnosed cancer in both men and women. In 2008, an 
estimated 148,810 new cases were diagnosed, and 49,960 deaths from 
colorectal cancer occurred (ACS, 2008). Most colorectal cancers (CRC) 
develop through multiple mutations in the normal colonic mucosa, and evolve 
through the adenoma-carcinoma sequence (Fearon et al., 1990 and Kinzler et 
al., 1996).The development of CRC is a multi-step process, which can arise 
due to cumulative effect of mutations in various different oncogenes, tumor 
suppressor genes and/or from epigenetic changes in DNA (Mustafa et al., 
2007). Recent progresses made in the field of molecular biology have shed 
light on the different alternative pathways involved in the colorectal 
carcinogenesis, and more importantly cross talk among these pathways 
(Risques et al., 2003 and Takayama et al., 2006). Various endogenous and 
exogenous agents from environmental exposures are constantly damaging 
DNA, and in combination with low DNA repair capacity this have been 
interpreted as increasing the likelihood of cancer development (Wei et al., 
1995;1996; Cheng et al., 1998; Shi et al., 2004).  
Colon being the waste processor of our body is in particular exposed to a wide 
array of endo as well as exogenous chemicals. Normally detoxification 
reactions are going on in our body at all the times and sometimes these lead to 
the production of certain harmful chemical compounds e.g, Lithocholic acid 
(LCA) (component of bile acids) is implicated in human and experimental 
animal carcinogenesis. Its effect on apoptosis and proliferation of the colonic 
epithelium was studied in a 1, 2-dimethylhydrazine (DMH)-induced murine 
carcinogenesis model (Vassilikki et al., 2000). On the other hand we eat a 
variety of compounds both natural and manmade and these contain a cocktail 
of chemicals which have a potential of acting as carcinogens like mono sodium 
glutamate, poly aromatic hydrocarbons, nitrosamines (Siddiqi et al., 1992). As 
colon is always in direct contact with these types of chemicals it can be 
understood as to why there is a high occurrence of colorectal cancer in general 
population.  
One of the most important treatment of this fatal cancer is surgery and 
subsequent chemotherapy and radiotherapy. For this purpose, it is important to 
identify the occurrence of genetic alterations as a new parameter to estimate the 
malignancy of the cancer. 
Tumor suppressor genes were initially hypothesized to be inactivated in cancer 
cells as a result of genetic defects of both alleles (i.e., the Knudson two-hit 
hypothesis). However, there is now evidence that epigenetic events, such as 
hypermethylation of cytosine–guanine (CpG) sites in regulatory regions (e.g., 
the promoter), may be a critical alternative mechanism of tumor suppressor 
gene inactivation. Epigenetic mechanisms of gene inactivation, including 
promoter hypermethylation, are undoubtedly important in cancer development 
and represent an alternative means of inactivating tumor suppressor genes. 
Nevertheless, the standard of proof for establishing that hypermethylation of 
the promoter of any given gene has a critical role in loss of gene expression 
and cancer development should probably be set quite high, regardless of 
whether the gene is a well-established tumor suppressor gene, like p16, or a 
potential tumor suppressor gene. However, before accepting the conclusion 
that hypermethylation of tumor suppressor gene promoters is invariably the 
cause of gene inactivation, it is worth evaluating the data a bit more critically. 
The current study was aimed: 
 To study the promoter hypermethylation status of p16 gene in 
colorectal cancer subjects of Kashmiri origin and correlate them with 
histopathologically confirmed controls. 
DNA methylation involves addition of a methyl group to the carbon 5 position 
of the cytosine ring. This reaction is catalyzed by DNA methyltransferases in 
the context of the sequence 5’-CG-3’, which is also referred to as a CpG 
dinucleotide (Singal and Ginder, 1999; Jones and Laired, 1999). The 
methylation of gene, particularly the methylation of CpG-rich promoters, could 
block transcriptional activation (Singal and Ginder, 1999; Jones and Laired, 
1999). A family
 
of three enzymes, the cytosine-DNA methyltransferases, 
catalyzes
 
methylation of the 5th position of the cytosine ring, using
 
S-
adenosylmethionine as the donor molecule. When this occurs
 
within a CpG 
island located in the promoter region of a gene,
 
it is also accompanied by 
changes in chromatin composition around
 
the island that denies access to 
regulatory proteins needed
 
for transcription. The chromatin structure is 
modified during
 
gene silencing by affecting acetylation, phosphorylation, 
methylation,
 
and/or ubiquitylation of histone tails (Jones and Baylin, 2002 and 
Kelly et al., 2002). Transcriptional
 
silencing by CpG island hypermethylation 
affects genes involved
 
in all aspects of normal cell function and now rivals 
genetic
 
changes that affect coding sequence as a critical trigger for
 
neoplastic 
development and progression (Jones and Laird, 1999; Baylin and Herman, 
2000). The rapid advance
 
in the study of gene-promoter hypermethylation in 
cancer was
 
facilitated by the development of the methylation specific PCR
 
(MSP) assay that allows for rapid detection of methylation in
 
genes through the 
selective amplification of methylated alleles
 
within a specific gene promoter 
(Herman et al., 1996). Gene promoter hypermethylation
 
has become a target 
for developing strategies to provide molecular
 
screening for early detection, 
diagnosis, prevention, treatment,
 
and prognosis of cancer. The effectiveness of 
gene promoter hypermethylation for cancer
 
screening and diagnosis ideally 
requires genes whose dysfunction
 
occurs early in tumour development, are 
specific to a particular
 
cancer, and a biological fluid or access to tissue that is 
specific
 
to the disease being assessed. For the majority of cancers,
 
it is difficult 
to meet all three of these criteria. This approach involves the detection of gene 
promoter
 
regions that are aberrantly hypermethylated in human tumours.
 
This 
change is associated with an epigenetically mediated gene
 
silencing that 
constitutes an alternative to coding region mutations
 
for loss of gene function 
(Jones and Baylin, 2002; Herman and Baylin, 2003). Gene silencing involves 
the
 
modification of both the genetic and histone code (Jones and Baylin, 2002). 
P16 tumour suppressor gene plays a monitor role in the passage of cells 
through the G1 to S phase of the cell cycle by binding to cyclin-dependent 
kinase 4 and inhibiting its effect on cyclin D1 (Merlo et al., 1995; wiser et al., 
1999; Yu  and Huang, 1999). The exon 1 coding sequences of the p16 gene 
resides within 5’ CpG islands. This area is not methylated in most normal tissues 
but methylated in many human cancers. Methylation of cytosine residues at CpG 
sites in p16 gene promotor, resulting in a silenced p16 expression, has been 
reported in many cell lines, including CRC, and some primary carcinomas in 
varied origins, such as colon, brain, breast, bladder, ovary, lung, and myeloma 
and so on (Esteller et al., 1999). The p16 methylation is common in CRC cell 
lines (Guan et al., 1999) and has been suggested to involve also in the primary 
CRC (Guan et al., 1999). Although most of authors hold the traditional 
viewpoint that detectable p16 methylation necessarily link to the inactivation of 
p16 protein, or transcriptional silencing of p16 gene (Baylin et al., 1998), 
coexistence of p16 methylation and p16 expression in one specimen has been 
frequently described (Wiencke et al., 1999). The elucidation of the relationship 
between p16 gene methylation and CRC will certainly help better understand 
the role of methylation of tumour suppressor genes in carcinogenesis. In the 
present study, frequent methylation of p16 was observed in colorectal cancer. 
In this study, p16 methylation was significantly associated with CRC. This 
result suggested that p16 methylation might link to a more malignant outcome 
of CRC.  
In the present study MSP was used for analysis of the methylation status of p16 
gene. This method provided significant advantages over previous ones used for 
assaying methylation. MSP is much more sensitive than Southern analysis, 
facilitating the detection of low numbers of methylated alleles and the study of 
DNA from small samples. MSP allows examination of all CpG sites, not just 
those within sequences recognized by methylation sensitive restriction 
enzymes. Fresh human tumour samples often contain normal and tumour 
tissue, making the detection of changes specific for the tumour difficult. 
However, the sensitivity of MSP suggests it would be useful for primary 
tumours as well, allowing for detection of aberrantly methylated alleles even if 
they contribute relatively little to the overall DNA in a sample.  
Considering the important role of promoter methylation in inactivation of p16 
which is one of the most frequently altered genes in squamous cell carcinoma 
of oesophagus and many other human cancers, in the present study, the level of 
p16 promoter methylation was investigated in colorectal carcinoma tissues of 
patients from Kashmir valley where frequency of colorectal cancer is higher.  
There were 50 histopathologically confirmed cancer cases and 20 
histopathologically confirmed normal cases as controls. Out of 50 cases 29 
were males which corresponded to 58% and hence 21 cases out of 50 were 
females which corresponded to 42%. The male to female ratio of the cancer 
came to 1.38. However, among normal cases 10 were males and 10 were 
females with male to female ratio of 1. All the patients were symptomatic at 
the time of diagnosis. Clinicopathological data revealed that the patients 
presented with abdominal pain, change in bowel habits, rectal bleeding and 
loss of appetite. The other signs and symptoms were subjective weight loss, 
abdominal mass, vomiting or abdominal distention and anemia. Of all the ten 
districts highest number of colorectal cases turned out from Srinagar and 
Budgam districts of Kashmir. 
The distribution of tumor was 60% (n = 30) in colon and 40% (n = 20) in 
rectum. Among colon cases 26% (n = 13) in sigmoid colon, 16 %( n=8) in 
ascending colon, 8 %( n=4) in transverse colon and 10% (n = 5) in descending 
colon. According to the classification of International Union against Cancer, 
there were 7 patients (14%) in stage I, 25(50%) in stage II, 11 (22%) in stage 
III and 7 (14%) in stage IV disease. Metastasis was found in 7 patients with 
distant metastasis in liver (n = 4) and lymph nodes (n = 5). All tumours were 
adenocarcinomas and on histological examination, 11 were well differentiated, 
31 moderately differentiated and 8 poorly differentiated adenocarcinomas. 
The genetic analysis of the cases and controls revealed that unlike other high 
risk regions, Kashmiri population has a different hypermethylation profile of 
p16 promoter. It was found that two-third i.e. 66% (33/50) of the cases had p16 
promoter hypermethylation while as one-third i.e. 33% (17/50) of the cases 
were nonmethylated. The study also reveals that 20% (4/20) of the controls 
also had promoter hypermethylation of CpG islands of p16 gene and 80% 
(16/20) did not showed promoter hypermethylation of CpG islands of p16 
gene. It was noticeable that, in this study, band U, i.e. PCR products amplified 
by primer U, was visible not only in 17 CRC cases and 16 controls which 
showed unhypermethylated p16 but also in few cases among other CRC 
specimen. Similar results were also reported by other investigators (Wiencke et 
al., 1999). This might first be attributed to the contamination of non-neoplastic 
cells that naturally harbored unmethylated DNA that could be derived from 
normal adjoining mucosal cells and from normal constituents in the stroma 
such as vascular endothelial cells, smooth muscles, fibroblasts and 
inflammatory cells. However, Guan et al., 1999, demonstrated that band U 
appeared even in the samples acquired by micro dissection which got rid of the 
non-neoplastic cells (Guan et al., 1999). This indicated the possibility that 
tumour cells in one sample were virtually the mixture of those contained 
methylated and unmethylated DNA. The association of promoter 
hypermethylation with colorectal cancer was found to be significant.  
The relationship between the promoter hypermethylation of p16 gene and 
several clinicopathological parameters was examined. These parameters 
included gender, clinical staging and histological grade. Occurrence of p16 
methylation was found to be unequally distributed in males and females with 
more frequency in males than in females. Among 29 males, 20 cases were 
hypermethylated and 9 cases were unhypermethylated. However among 10 
male controls 2 cases were hypermethylated and 8 cases were 
nonhypermethylated. The association of promoter hypermethylation with 
colorectal cancer was found to be significant in males. In comparison, among 
21 females, 13 cases were hypermethylated and 8 cases were 
nonhypermethylated. However among 10 female controls 1 case was 
hypermethylated and 9 cases were nonhypermethylated. The association of 
promoter hypermethylation with colorectal cancer was again found to be 
significant in females too. Also on comparing the male cases with female 
cases, 20 cases were hypermethylated and 9 cases were unhypermethylated in 
males and 13 cases were hypermethylated and 8 cases were unhypermethylated 
in females, occurrence of p16 methylation was found to be unequally 
distributed in males and females with more frequency in males than in females 
but the difference was not statistically significant. 
Among the 32 patients who were in stage I and stage II, 18 cases showed 
promoter hypermethylation and 14 cases were nonhypermethylated. However 
among 18 patients who were in stage III and stage IV, 15 cases showed 
promoter hypermethylation and 3 cases were nonhypermethylated. When the 
frequency of p16 promoter hypermethylation was compared with clinical 
staging of the disease, p16 promoter hypermethylation was found to be 
certainly higher in Stage III/IV (83.33%) compared to Stage I/ II (56.25%) but 
the difference was not statistically significant. 
Status of p16 promoter hypermethylation was not found to correlate well with 
histological grades of the disease. Among 11 cases who were histologically 
well differentiated adenocarcinoma cases, 6 cases i.e., 54.54% (6/11) showed 
promoter hypermethylation and 5 cases were nonhypermethylated. From 31 
moderately differentiated adenocarcinoma cases, 21 cases i.e., 67.74% (21/31) 
showed promoter hypermethylation and 10 cases were nonhypermethylated 
and among 8 poorly differentiated adenocarcinoma cases 6 cases i.e., 75% 
(6/8) showed promoter hypermethylation and 2 cases were 
nonhypermethylated. So, the degree of p16 promoter hypermethylation 
increased with the increasing severity of the lesion but the difference was not 
statistically significant.  
The study on colorectal cancer showed that more than 50% tissues expressed 
methylated p16 promoter. Therefore, it is quite possible that like other 
geographical regions, methylation of promoter of p16 gene is the major 
epigenetic event in colorectal cancer in the Kashmir valley. We observed 
completely methylated p16 promoter in 33 cases out of 50. Though there was 
no selection bias in sampling, occurrence of p16 methylation was found to be 
unequally distributed in males and females with more frequency in males than 
in females. Our study also showed that p16 promoter hyper methylation was 
found to be certainly higher in Stage III/IV compared to Stage I/ II but the 
difference was not statistically significant. The study also showed that the 
degree of p16 promoter hypermethylation increased with the increasing 
severity of the lesion but the difference was not again statistically significant. 
This study from India demonstrates that p16 promoter methylation is a frequent 
epigenetic event in colorectal cancer of the Kashmir region. These results also 
indicate that p16 aberrant methylation may play an important role in colorectal 
cancer development. Therapeutic strategies targeting promoter 
hypermethylation may be highly beneficial in the Kashmiri population and 
other specific regions where incidence of colorectal cancer is associated with 
high frequency of p16 promoter methylation. The data gives a clue that p16 
gene expression can be readily and fully restored and growth rate of cancer 
cells decreased by treatment of cancer cells with demethylating agents and 
DNA methylation inhibitors. The administration of drugs such as cytosine 
analogs might be able to restore the function of these tumour suppressor genes 
and slow the rate of colorectal cancer progression. It also demonstrates that 
hypermethylation of p16 gene can be designated as epigenetic biomarker for 
the screening, diagnosis and prognosis of colorectal cancer.  
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Appendix 
Chemicals and Reagents 
CHEMICALS 
Chemical Name Company 
Absolute ethanol BENGAL CHEMICALS 
Acetone GALAXO LABORATORIES 
Agarose MP BIOMEDICALS 
Ammonium  chloride BDH 
Ammonium acetate BDH 
Bromophenol blue SARABHAI  M  CHEMICALS 
Chloroform THOMAS BAKERS 
De Ionized water ALFA LABORATORIES 
Ethedium bromide SRL 
Ethyl acetate MERCK 
Ethylene diamine tetra acetate LOBA CHEMIE 
Formaldehyde GALAXO LABORATORIES 
Glacial acetic acid MERCK 
Hydrochloric acid S D FINE CHEMICALS 
Hydrogen peroxide MERCK 
8-Hydroxyquinoline CDH 
Isoamyl alcohol BDH 
Isopropanol THOMAS BAKERS 
Magnesium chloride MERCK 
Methanol SARABHAI  M  CHEMICALS 
Phenol  SRL 
Potassium acetate QUALGENS 
Potassium bicarbonate QUALGENS 
Potassium chloride LOBA- CHEMIE 
Potassium hydroxide S D FINE CHEMICALS 
2-Propanol MERCK 
Sodium acetate SARABHAI  M  CHEMICALS 
Sodium azide LOBA CHEMIE 
Sodiun bisulphate LOBA CHEMIE 
Sodium carbonate FIZMERCK 
Sodium chloride MERCK 
Sodium dodecyl sulphate MP BIOMEDICALS 
Sodium hydroxide HEMEDIA 
Sodium hydrogen carbonate LOBA- CHEMIE 
Sodium phosphate dibasic LOBA- CHEMIE 
Sodiun thiosulfate LOBA CHEMIE 
Sucrose QUALGENS 
Sulfuric acid MERCK 
TE buffer SRL 
Tris base SIGMA CHEMICAL COMPANY 
Tris HCL HIMEDIA 
Triton X 100 S D FINE CHEMICALS 
 
 
ENZYMES 
 
 
Taq polymerase 
 
FERMENTAS /  BIOTOOLS 
Proteinase K ZYMO RESEARCH 
 
 
MISCELLANEOUS  MATERIAL 
 
 
100bp DNA ladder 
 
FERMENTAS / BIO ENZYME 
 
 
PCR  REAGENTS 
 
 
10 X Buffer (with Mgcl2) 
 
BIOTOOLS 
dNTPs  CINNAGEN 
Primers (methylated and  
unmethylated) 
GENESCRIPT 
Universal Methylated Human DNA 
Standard and Control with primers 
ZYMO RESEARCH 
 
DNA Isolation: 
DNA was iosolated by kit based method. The kit used was Quick- g DNA
TM 
MiniPrep supplied by ZYMO RESEARCH. The protocol followed was as 
directed by the company. 
 
DNA storage buffer: 
0.5 M EDTA        0.01 ml 
1 M Tris        0.5 ml 
Final volume was made 50 ml with sterile distilled water. 
 
DNA Bisulfite Modification: 
DNA was modified by kit based method, the kit used was EZ DNA 
Methylation
TM
 Kit supplied by ZYMO RESEARCH. The protocol followed 
was as directed by the company. 
 
REAGENTS FOR AGAROSE GEL ELECTROPHORESIS: 
Agrose  1%:                  
Agarose        0.5g 
Buffer         50ml 
EtBr         10µl 
Agarose was dissolved in a buffer and heated till a clear solution is formed. 
EtBr was then added to the solution during its cooling just before being poured 
into the casting tray. 
 
Bromophenol Blue: 
Bromophenol Blue       0.4g 
Sucrose        20.0g 
Bromophenol blue was dissolved in 100ml of distilled water. 
From the above stock solution 31.25ml was taken and sucrose was added. Final 
volume was made 50ml with distilled water. 
Ehedium Bromide 
Ethedium bromide       10mg 
Ehedium Bromide was dissolved in 1ml of distilled water. The solution was 
stored in a dark bottle at 4˚C. 
 
 
50X TAE (pH 8.0) STOCK SOLUTION: 
Tris base        242g 
0.5M         100ml 
Glacial acetic acid       57.1ml 
Final volume was made 1000ml with distilled water. This is stock solution. 
 
1X TAE (pH 8.0) WORKING SOLUTION: 
50 X TAE        20ml 
Final volume was made 1000ml with distilled water. 
 
Reagents for PCR: 
Stock 
Deoxyribosenucleotidetriphosphate (dNTP) 100mM each dATP, dGTP, dCTP 
and dTTP. 
Taq polymerase (5U/ml ) 
10X Taq buffer  (16 mmol/L ammonium sulfate, 67 mmol/L Tris- HCL, pH 
8.8, 10 mmol/L 2-mercaptoethanol), 6.7 mmol/ L MgCl2) 
Primers: 100pM in sterile deionised water (Genescript)  
100bp DNA ladder (0.5µg/µl) 
 
 
 
